Physician profile
Gregory Schlessinger
NPI 1255313441
$3,645.48
in general payments reported to CMS, 2019-2025
21 companies · $492 in 2025
The $492 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $219 · 2021: $1,577 · 2022: $333 · 2023: $365 · 2024: $515 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,355 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,355.11 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,080.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $495.17 | 2020-2024 | Farxiga |
| Amgen INC. | $372.21 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Bayer Healthcare Pharmaceuticals INC. | $203.09 | 2022-2025 | |
| Glaxosmithkline, LLC. | $186.86 | 2021-2025 | Benlysta |
| Nxstage Medical, INC. | $186.17 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $180.33 | 2022-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $160.38 | 2019-2024 | Veltassa |
| Akebia Therapeutics INC | $143.18 | 2024-2025 | Vafseo, Auryxia |
| Calliditas Therapeutics US INC. | $108.64 | 2023-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $79.30 | 2022-2025 | |
| Horizon Therapeutics Plc | $77.48 | 2022-2023 | Krystexxa |
| Apellis Pharmaceuticals, INC. | $71.34 | 2025 | Empaveli |
| Novo Nordisk INC | $64.69 | 2024-2025 | Rivfloza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.42 | 2024-2025 | Jardiance |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $55.21 | 2019-2024 | Ultomiris |
| Aurinia Pharma U.S., INC. | $41.04 | 2021-2022 | |
| Daiichi Sankyo INC. | $30.12 | 2024 | Injectafer |
| Merck Sharp & Dohme LLC | $22.63 | 2025 | Prevymis |
| Novartis Pharmaceuticals Corporation | $16.69 | 2025 | |
| Scpharmaceuticals INC. | $15.53 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Schlessinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.